SOPHiA GENETICS SA (SOPH)Healthcare | Health Information Services | Rolle, Switzerland | NasdaqGS
5.74 USD
+0.06
(1.056%)
⇧
(July 15, 2026, 3:02 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:13 a.m. EDT
The investment case here is severely compromised by a deteriorating business reality. The company is burning cash aggressively, with operating cash flow and free cash flow both deeply negative, while returning equity to insiders via sales to cover taxes. Fundamentally, the stock is trading at a loss with negative returns on assets and equity, and the balance sheet shows significant leverage relative to equity. While revenue growth remains positive at 22%, the market has punished the stock hard, wiping out nearly 80% of its value over the last four years. The recent price action shows a slight bounce off lows, but the underlying fundamentals—specifically the inability to generate profit or cash—remain a critical flaw. With no dividend to provide income and a weak statistical forecast, the outlook appears bleak for both immediate and long-term holders. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.055907 |
| AutoETS | 0.055908 |
| MSTL | 0.063325 |
| AutoTheta | 0.063589 |
| MSTL_78 | 0.071157 |
| MSTL_78_113 | 0.080934 |
| MSTL_113 | 0.086595 |
Forecast horizon: 60 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 5.29 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.670 |
| Excess Kurtosis | -0.28 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 136.633 |
| Revenue per Share | 1.181 |
| Market Cap | 481,558,784 |
| Forward P/E | -10.25 |
| Beta | 0.96 |
| Profit Margins | -99.70% |
| Website | https://www.sophiagenetics.com |
As of July 11, 2026, 5:13 a.m. EDT: Speculator positioning is extremely thin and fragmented. In the near term (July/August), there is negligible open interest on both sides, suggesting a lack of defined directional bets. As expiration extends to September and December, put volume and open interest significantly outpace calls, particularly at the money strikes. This imbalance indicates a speculative bias toward downside protection rather than aggressive upside speculation, reflecting skepticism about the stock's ability to recover quickly.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5690608 |
| Address1 | La PiEce 12 |
| All Time High | 19.8 |
| All Time Low | 1.685 |
| Ask | 7.36 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 369,640 |
| Average Daily Volume3 Month | 200,314 |
| Average Volume | 200,314 |
| Average Volume10Days | 369,640 |
| Beta | 0.958 |
| Bid | 4.2 |
| Bid Size | 1 |
| Book Value | 0.636 |
| City | Rolle |
| Compensation As Of Epoch Date | 1,672,444,800 |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.74 |
| Current Ratio | 2.056 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 5.87 |
| Day Low | 5.69 |
| Debt To Equity | 136.633 |
| Earnings Call Timestamp End | 1,777,982,400 |
| Earnings Call Timestamp Start | 1,777,982,400 |
| Earnings Timestamp | 1,777,984,200 |
| Earnings Timestamp End | 1,785,846,600 |
| Earnings Timestamp Start | 1,785,846,600 |
| Ebitda | -70,322,000 |
| Ebitda Margins | -0.86625 |
| Enterprise To Ebitda | -5.756 |
| Enterprise To Revenue | 4.986 |
| Enterprise Value | 404,802,272 |
| Eps Current Year | -0.78 |
| Eps Forward | -0.56 |
| Eps Trailing Twelve Months | -1.18 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.1922 |
| Fifty Day Average Change | 0.5477996 |
| Fifty Day Average Change Percent | 0.10550433 |
| Fifty Two Week Change Percent | 56.906082 |
| Fifty Two Week High | 6.3 |
| Fifty Two Week High Change | -0.5600004 |
| Fifty Two Week High Change Percent | -0.08888895 |
| Fifty Two Week Low | 2.92 |
| Fifty Two Week Low Change | 2.8199997 |
| Fifty Two Week Low Change Percent | 0.9657533 |
| Fifty Two Week Range | 2.92 - 6.3 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,047,000,000 |
| Float Shares | 54,689,901 |
| Forward Eps | -0.56 |
| Forward P E | -10.25 |
| Free Cashflow | -24,592,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 415 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.6728 |
| Gross Profits | 54,618,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07219 |
| Held Percent Institutions | 0.48037 |
| Implied Shares Outstanding | 83,895,266 |
| Industry | Health Information Services |
| Industry Disp | Health Information Services |
| Industry Key | health-information-services |
| Ipo Expected Date | 2,021-07-23 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom. The company was incorporated in 2011 and is based in Rolle, Switzerland. |
| Long Name | SOPHiA GENETICS SA |
| Market | us_market |
| Market Cap | 481,558,784 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_237555193 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -80,936,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 476,525,110 |
| Number Of Analyst Opinions | 3 |
| Open | 5.75 |
| Operating Cashflow | -40,263,000 |
| Operating Margins | -0.79689 |
| Payout Ratio | 0.0 |
| Phone | 41 21 694 10 60 |
| Previous Close | 5.68 |
| Price Eps Current Year | -7.3589745 |
| Price Hint | 2 |
| Price To Book | 9.025157 |
| Price To Sales Trailing12 Months | 5.931988 |
| Profit Margins | -0.99698997 |
| Quick Ratio | 1.711 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.059999943 |
| Regular Market Change Percent | 1.056337 |
| Regular Market Day High | 5.87 |
| Regular Market Day Low | 5.69 |
| Regular Market Day Range | 5.69 - 5.87 |
| Regular Market Open | 5.75 |
| Regular Market Previous Close | 5.68 |
| Regular Market Price | 5.74 |
| Regular Market Time | 1,784,142,164 |
| Regular Market Volume | 215,552 |
| Return On Assets | -0.29708 |
| Return On Equity | -1.2328299 |
| Revenue Growth | 0.22 |
| Revenue Per Share | 1.181 |
| Sand P52 Week Change | 0.2043345 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 83,895,266 |
| Shares Percent Shares Out | 0.0076 |
| Shares Short | 636,132 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 279,103 |
| Short Name | SOPHiA GENETICS SA |
| Short Percent Of Float | 0.0081 |
| Short Ratio | 2.13 |
| Source Interval | 15 |
| Symbol | SOPH |
| Target High Price | 9.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 8.0 |
| Target Median Price | 8.0 |
| Total Cash | 65,392,000 |
| Total Cash Per Share | 0.911 |
| Total Debt | 62,425,000 |
| Total Revenue | 81,180,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.18 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.8406 |
| Two Hundred Day Average Change | 0.89939976 |
| Two Hundred Day Average Change Percent | 0.18580337 |
| Type Disp | Equity |
| Volume | 215,552 |
| Website | https://www.sophiagenetics.com |
| Zip | 1,180 |